Abstract 4124
Background
Lung cancer is one of the most fatal cancer types globally. Currently, the immune status in the tumor microenvironment (TME) is highly valued. The immune status includes the expression of checkpoint molecules, co-stimulatory molecules, tumor-infiltrated lymphocyte status and TCR signal status, etc., which harbor different mechanisms in regulating the immune cells in the TME. However, the expression status of some biomarkers may have inner statistical characteristics, which may leave clues to the immune status and related clinical outcomes. In this study, a panel of 9 immune biomarkers was selected for the possible prediction of clinical outcomes in early stage resectable NSCLC.
Methods
Immunohistochemistry (IHC) was performed on surgical samples from 139 patients with NSCLC. Cox regression analysis and subgroup analysis of OS and RFS were conducted for the screening of biomarkers. The Principle Component Analysis (PCA) was conducted on screened biomarkers, including factorial analysis, principle component regression and principle component ranking. A database search was performed in order to verify the clinical characteristics. An Artificial Neuron Network analysis was established for the prediction of clinical outcomes.
Results
6 out of 9 biomarkers are considered significant and were selected for the data analysis. The KMO-Bartlett’s Sphericity test is valid (0.658>0.5, p = 0.0001). The principle component regression results indicate the OS is correlated with the principle component Z4(Y = 0.316×Z4 + 2.298, R = 0.189, p = 0.026). Also, the PFS also correlated with the principle component Z4 and Z2 (Y = 0.314×Z4 + 0.255×Z2 + 2.061, R = 0.249, p = 0.013). Principle components ranking (PCrank) is calculated and after the determination of cutoff 0.2, the intergroup comparison of subgrouphigh and subgrouplow is significant in OS (p = 0.025). Database searching validates our results. The ANN model successfully predicts the clinical outcome, with the testing accuracy of 94.1% and 96.2% in models 1 and 2, respectively.
Conclusions
The selected immunological panel has promising potential in predicting the prognosis of resectable NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by a grant from National Natural Science Foundation of China (81802255), Shanghai Pujiang Program (17PJD036) and a grant from Shanghai Municipal Commission of Health and Family Planning Program (20174Y0131). National key research & development project (2016YFC0902300). Major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC (16CR1001A). The fundamental research funds for the central universities.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract